Tectonic Therapeutic Inc (TECX)

$54.84 +29.12 (113.22%)
Market Cap 360.56M
Revenue (ttm) 0.00
Net Income (ttm) 12.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,543,600
Avg Vol 140,538
Day's Range N/A - N/A
Shares Out 14.75M
Stochastic %K 32%
Beta 2.63
Analysts Strong Sell
Price Target $74.67

Latest News on TECX

Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

Jan 30, 2025, 6:30 AM EST - 14 hours ago

Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

Tectonic Therapeutic: Protein Engineering Platform For GPCRs

Jan 5, 2025, 7:30 AM EST - 25 days ago

Tectonic Therapeutic: Protein Engineering Platform For GPCRs

Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024

Dec 3, 2024, 4:01 PM EST - 2 months ago

Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024

Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference

Nov 26, 2024, 4:01 PM EST - 2 months ago

Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference

Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein

Nov 11, 2024, 5:00 AM EST - 2 months ago

Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein

Tectonic Therapeutic to Present Phase 1a Data at AHA 2024

Oct 22, 2024, 4:01 PM EDT - 3 months ago

Tectonic Therapeutic to Present Phase 1a Data at AHA 2024

Tectonic Therapeutic: Interesting CV Disease Drug Developer

Oct 20, 2024, 6:02 AM EDT - 3 months ago

Tectonic Therapeutic: Interesting CV Disease Drug Developer

Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45

Sep 19, 2024, 4:01 PM EDT - 4 months ago

Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45

Tectonic Therapeutic to Participate in September Investor Conferences

Aug 20, 2024, 4:01 PM EDT - 5 months ago

Tectonic Therapeutic to Participate in September Investor Conferences

Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 14, 2024, 4:01 PM EDT - 6 months ago

Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45

Jul 30, 2024, 4:01 PM EDT - 6 months ago

Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45